You know that feeling you get when you look at something and it just doesn't seem right?
And the feeling you get when you compare similar things and find that there is an explainable disparity?
They are the feelings I get when I look at the MEB market capitalization and compare it to other start-up companies in the Med Tech scene.
There is a massive re-rate on the horizon for MEB.......this little gem has been way undervalued for way too long! Great John Hopkins results would virtually ensure that FDA approval would occur in 2017, resulting in the share price moving violently in an upwards direction and shooting past $1
